Loading organizations...

§ Private Profile · Berkeley, CA, USA
AI voice biomarker technology detects depression and anxiety from speech, offering a SaaS API platform for healthcare mental health screening.
Kintsugi, based in Berkeley, California, develops AI-powered voice biomarker technology, Kintsugi Voice, designed to detect signs of clinical depression and anxiety from short speech clips. The platform integrates as a SaaS API into healthcare settings like call centers and telehealth, enabling early mental health screening while anonymizing identifiable information. Kintsugi has raised $28 million in total funding since 2019, including a $20 million Series A in 2023 led by Insight Partners, with Acrew Capital and Darling Ventures also investing. Its technology, capable of analyzing speech clips as brief as 20 seconds, is licensed to healthcare providers, payers, and pharmaceutical companies. Prentice Tom, MD, serves as Chief Medical Officer. Kintsugi was founded in 2019 by Grace Chang and Rima Seiilova-Olson. Its business model centers on saaS API platform licensed to healthcare providers, payers, health systems, pharmaceutical companies, and enterprises like Fortune 500 care management call centers.
Kintsugi has raised $29.0M across 4 funding rounds.
Kintsugi has raised $29.0M in total across 4 funding rounds.
Kintsugi is a health technology company developing AI-driven voice biomarker software to detect signs of depression and anxiety from short clips of free-form speech, enabling scalable mental healthcare access.[1][2][3][5][6] Its primary product, Kintsugi Voice (KiVA), is an API-first platform that integrates with call centers, telehealth systems, and remote patient monitoring apps, serving health systems, payers, providers, and enterprises by providing real-time, language-agnostic mental health screenings without relying on speech content.[2][3][4][6] The technology addresses gaps in traditional screening methods like PHQ-9 and GAD-7 questionnaires, helping clinicians triage patients faster and improve outcomes amid rising mental health needs, with integrations already in Fortune 500 care management call centers.[3][6] Founded in 2019, Kintsugi has raised over $26.5 million by 2022, earned recognitions like Forbes’ Top 50 AI Companies (2022) and Gartner Cool Vendor, and demonstrated growth through NSF grants and awards.[1][3][4][5][6]
Kintsugi was co-founded in 2019 by Grace Chang, a software engineer and CEO, and Rima Seiilova-Olson, a machine learning scientist, both motivated by personal challenges accessing quality mental health services through their healthcare providers.[3][5] Based in the Bay Area, California, the duo combined their expertise to create AI voice biomarker technology, drawing inspiration from the Japanese art of kintsugi—repairing broken ceramics with gold to make them stronger and more beautiful—symbolizing improved mental health access.[5][6] A pivotal early moment came in October 2019 with a Phase I NSF grant for AI development, followed by 2020 NSF I-Corps participation that refined their go-to-market strategy through customer discovery.[4][5] Initial traction built via KiVA's integration into clinical workflows, leading to $8 million in seed funding and a $20 million Series A in 2022 (totaling over $26.5 million), fueling team expansion in marketing, business, and operations.[3][4]
(Note: A separate sales tax compliance company named Kintsugi exists for ecommerce/SaaS but is unrelated to this health tech firm.[7])
Kintsugi rides the AI-for-healthcare wave, specifically vocal biomarkers amid a mental health crisis where depression affects 80% of chronic conditions and traditional screenings falter under scale demands.[3][6] Timing aligns with post-pandemic telehealth booms and AI adoption in clinical decision support, as payers and providers seek efficient triage to cut costs and save lives—e.g., integrating with remote monitoring to flag risks instantly.[1][3] Market tailwinds include exploding demand for non-invasive diagnostics, regulatory support for AI (e.g., NSF backing), and shifts from reactive to predictive care, positioning Kintsugi to influence ecosystems by standardizing voice-based mental health screening across global health systems.[4][5][6]
Kintsugi is poised to expand KiVA into pharmaceuticals and SMEs, leveraging its $20M+ funding for global scaling and deeper integrations amid AI health tech maturation.[3][4] Trends like multimodal AI (combining voice with wearables) and value-based care will amplify its edge, potentially evolving it into a mental health platform leader as voice data standards emerge. With ethical AI leadership, expect growing influence in closing care gaps—transforming "broken" access into resilient, gold-standard screening, true to its name.
Kintsugi has raised $29.0M across 4 funding rounds. Most recently, it raised $20.0M Series A in February 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2022 | $20M Series A | Insight Partners | Darling Ventures, Acrew Capital, Robey Miller, Adam Grosser, Eric Yuan | Announced |
| Aug 1, 2021 | $8M Seed | Acrew Capital | Darling Ventures, DST Global, GE Ventures, Andrew Wheeler, MS&AD Ventures, Marc VAN DEN Berg, Sequoia Capital, UP.Partners, RON Pragides, Adam Grosser, Eric Yuan, ON Deck, Techstars | Announced |
| Nov 1, 2020 | $1M Seed | — | Darling Ventures | Announced |
| Aug 1, 2020 | $20K Seed | — | Headwater Ventures, Innova Memphis | Announced |
Kintsugi has raised $29.0M in total across 4 funding rounds.
Kintsugi's investors include Insight Partners, Darling Ventures, Acrew Capital, Robey Miller, Adam Grosser, Eric Yuan, DST Global, GE Ventures, Andrew Wheeler, MS&AD Ventures, Marc van den Berg, Sequoia Capital.